Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
167 hedge funds and large institutions have $1.39B invested in Aerie Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 60 increasing their positions, 47 reducing their positions, and 36 closing their positions.
177% more call options, than puts
Call options by funds: $17.2M | Put options by funds: $6.21M
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
28% more capital invested
Capital invested by funds: $1.09B → $1.39B (+$304M)
28% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 47
0% more funds holding
Funds holding: 167 → 167 (0)
0% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$23.7M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$22.8M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$22.8M |
| 4 |
Citigroup
New York
|
+$19.1M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$57.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.2M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$20.3M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.5M |
| 5 |
Goldman Sachs
New York
|
-$7.41M |
AERI Hedge Fund Activity: Q4 2019 in Review
167 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2019, worth a combined $1.39B — up 28% from $1.09B a quarter earlier.
Fund positioning in AERI was balanced in Q4 2019: 36 funds opened new positions, 36 closed out, 60 added to existing stakes and 47 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $23.7M. The largest seller was Deerfield Management, cutting an estimated $57.9M.
- 167 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $1.39B of Aerie Pharmaceuticals stock for Q4 2019, up 28% quarter-over-quarter.
- 36 funds opened new Aerie Pharmaceuticals positions in Q4 2019 and 36 closed out, a net change of 0 holders.
- The largest Aerie Pharmaceuticals buyer in Q4 2019 was Franklin Resources, an estimated $23.7M added.
- The largest Aerie Pharmaceuticals seller in Q4 2019 was Deerfield Management, an estimated $57.9M sold.
Based on aggregated 13F filings for Q4 2019.